AgingResearch.NewsJoin free

Muna Therapeutics

CompanyDenmark

Muna Therapeutics develops one asset, in phase 1 (MNA-001 in Alzheimer's disease). Mostly small molecule acting on TREM2, proteostasis and autophagy; based in Denmark.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • MNA-001

    Activates TREM2 to enhance microglial function, resolve misfolded protein pathology, and protect neurons from degeneration.

    Phase 1, Small molecule, TREM2, Proteostasis, Alzheimer's disease, early-stage Alzheimer's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • People24
  • Similar companies6

Intelligence